Body Protective Comp
Ogunwobi OO, Puszyk W, Dong H-J, Liu C
Female reproductive tissue is responsive to cyclic hormones, estrogen and progesterone, and BPC-157s promotion of angiogenesis and decreased local inflammation could alter follicle microenvironment and endometrial lining quality
Human Safety Trials: TB-500 has undergone multiple Phase I and Phase II trials
Some notable safety-related conclusions from scientific materials include: A 2016 review of TB4 for dermal healing: The safety profile is excellent, and no preclinical toxicology has been found.22 A 2016 clinical trial on patients with STEMI: Our pilot study suggested that T4-optimized EPC transplantation appeared to be feasible and safe.34 A 2021 review of TB4 research: It was well tolerated and safe in healthy people and suitable for use in a clinical study.21 Though the compound itself may be generally safe for adults to use, some common side effects from TB4 injections reported by patients and doctors include: Injection site reactions (e.g., redness, mild swelling, or pain) Mild gastrointestinal symptoms Headaches and dizziness Rare but more serious side effects can include fever, blistering at the injection site, muscle aches, skin rash, vomiting, severe itching, or hives
Furthermore, BPC-157 stabilizes existing vascular structures and modulates vascular tone via NO-mediated vasodilation, thereby safeguarding tissues against ischemic damage during repair processes [20, 24, 41]
